Detailed view for EHI_162340

Basic information

TDR Targets ID: 803369
Entamoeba histolytica, serine/threonine protein kinase, putative
Source Database / ID:  AmoebaDB  

pI: 7.1862 | Length (AA): 607 | MW (Da): 71457 | Paralog Number: 0

Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0

Druggability Group : DG2

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF00069   Protein kinase domain

Gene Ontology

Mouse over links to read term descriptions.
GO:0005524   ATP binding  
GO:0004672   protein kinase activity  
GO:0006468   protein amino acid phosphorylation  

Metabolic Pathways

This gene is not mapped to any metabolic pathway in KEGG.

Structural information

Modbase 3D models:

There are 7 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
19 569 4oli (A) 595 1165 17.00 0 1 0.940943 0.78
278 607 3e7o (A) 11 307 28.00 0.00000064 1 0.623657 0.54
288 564 1fot (A) 85 325 33.00 0 1 0.647343 0.23
295 599 3mwu (A) 81 349 33.00 0 1 0.684471 0.32
297 514 2oid (A) 193 382 42.00 0.0000003 0.95 0.390143 0.68
388 569 3pp0 (A) 796 972 27.00 0 1 0.684035 -0.93
388 600 2w4o (A) 116 325 29.00 0 1 0.646106 -0.54

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein

Expression

Upregulation Percent Ranking Stage Dataset
Upper 60-80% percentile Rahman HM-1 IMSS Trophozoite. Hon CC
Upregulation Percent Ranking Stage Dataset
Mid 40-60% percentile Trophozoite. Hon CC
Show/Hide expression data references
  • Hon CC Transcriptomics of virulent and avirulent strains

Orthologs

Ortholog group members (OG5_199200)

Species Accession Gene Product
Entamoeba histolytica EHI_162340   serine/threonine protein kinase, putative

Essentiality

No essentiality data collected for this gene and/or its orthologs.

Phenotypes and Validation (curated)

We have no manually annotated phenotypes for this target. What does this mean? / Care to help?

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.

Annotated validation

No validation data for this target

Associated compounds / Druggability

Known modulators for this target

No chemical compounds associated to this gene

Predicted associations

By orthology with druggable targets
Non orthologous druggable targets
By sequence similarity to non orthologous druggable targets
Species Target Length Identity Alignment span Linked Drugs Reference
Rattus norvegicus Mitogen-activated protein kinase 1 358 aa 25.7% 296 aa Compounds References
Xenopus laevis Aurora kinase B-B 368 aa 29.1% 299 aa Compounds References
Xenopus laevis Aurora kinase B-A 361 aa 29.1% 299 aa Compounds References
Homo sapiens Cyclin-dependent kinase 1/cyclin B1 297 aa 25.5% 321 aa Compounds References
Rattus norvegicus cAMP-dependent protein kinase alpha-catalytic subunit 351 aa 27.0% 300 aa Compounds References
Schizosaccharomyces pombe 972h- Casein kinase II subunit alpha 332 aa 18.9% 328 aa Compounds References
Patiria pectinifera Cdc2 300 aa 25.9% 320 aa Compounds References
Plasmodium falciparum (isolate 3D7) Cell division control protein 2 homolog 288 aa 22.0% 268 aa Compounds References
Obtained from network model

Ranking Plot

Putative Drugs List

Compound Raw Global Species
0.0007 0.5 0.5
0.0023 0.5 0.5
0.0039 0.9485 0.5
0.0098 0.3242 0.3167
0.0008 0.5 0.5
0.0092 1 0.5
0.0029 0.5 0.5
0.0011 1 0.5
0.0062 0.6935 0
0.0059 1 1
0.0027 1 0.5
0.0016 0.5 0.5
0.0067 0.5 0.5
0.0066 0.3101 0
0.0026 0.5 0.5
0.0039 0.5 0.5
0.0036 0.5 0.5
0.0061 0.6883 0.6247
0.0042 0.5 0.5
0.0018 0.5 0.5
0.0069 0.3067 0.5
0.0059 1 1
0.0063 1 1
0.0033 0.5 0.5
0.0004 0.5 0.5
0.0091 1 0.5
0.0081 0.5 0.5
0.0007 0.5 0.5
0.0012 0.5 0.5
0.0033 1 1
0.0016 0.5 0.5
0.0007 0.5 0.5
0.0032 0.5 0.5
0.0039 0.5 0.5
0.0037 1 0.5
0.0012 0.5 0.5
0.0003 0.5 0.5
0.0012 0.5 0.5
0.0088 0.4477 0.5
0.0081 1 0.5
0.0056 1 0.5
0.0093 0.8828 0
0.0032 0.5 0.5
0.0063 0.7244 0
0.0059 1 1
0.0022 0.5 0.5
0.0064 0.3377 0.8757

Assayability

Assay information

No assay information for this target.

Reagent availability

No reagent availability information for this target.

Bibliographic References

No literature references available for this target.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier EHI_162340 (Entamoeba histolytica), serine/threonine protein kinase, putative
Title for this comment
Comment